CA2179183A1 - Interleukin-1 receptor antagonist decreases severity of acute pancreatitis - Google Patents

Interleukin-1 receptor antagonist decreases severity of acute pancreatitis

Info

Publication number
CA2179183A1
CA2179183A1 CA002179183A CA2179183A CA2179183A1 CA 2179183 A1 CA2179183 A1 CA 2179183A1 CA 002179183 A CA002179183 A CA 002179183A CA 2179183 A CA2179183 A CA 2179183A CA 2179183 A1 CA2179183 A1 CA 2179183A1
Authority
CA
Canada
Prior art keywords
interleukin
receptor antagonist
acute pancreatitis
antagonist decreases
decreases severity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002179183A
Other languages
French (fr)
Other versions
CA2179183C (en
Inventor
James G. Norman, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
James G. Norman, Jr.
University Of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James G. Norman, Jr., University Of South Florida filed Critical James G. Norman, Jr.
Publication of CA2179183A1 publication Critical patent/CA2179183A1/en
Application granted granted Critical
Publication of CA2179183C publication Critical patent/CA2179183C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A method for treating acute pancreatitis comprising administering an effective amount of Interleukin-1 receptor antagonist (IL-1ra) or a pharmaceutically acceptable salt thereof to a person afflicted with that condition.
CA002179183A 1993-12-15 1994-12-15 Interleukin-1 receptor antagonist decreases severity of acute pancreatitis Expired - Fee Related CA2179183C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US167,698 1980-07-11
US08/167,698 US5508262A (en) 1993-12-15 1993-12-15 Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
PCT/US1994/014572 WO1995016706A1 (en) 1993-12-15 1994-12-15 Interleukin-1 receptor antagonist decreases severity of acute pancreatitis

Publications (2)

Publication Number Publication Date
CA2179183A1 true CA2179183A1 (en) 1995-06-22
CA2179183C CA2179183C (en) 2006-12-05

Family

ID=22608442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002179183A Expired - Fee Related CA2179183C (en) 1993-12-15 1994-12-15 Interleukin-1 receptor antagonist decreases severity of acute pancreatitis

Country Status (5)

Country Link
US (2) US5508262A (en)
EP (1) EP0734395A4 (en)
JP (1) JPH09510434A (en)
CA (1) CA2179183C (en)
WO (1) WO1995016706A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5508262A (en) * 1993-12-15 1996-04-16 University Of South Florida Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US5972880A (en) * 1996-03-07 1999-10-26 Arthro Lab Inc. Method of treatment of osteoarthritis with interleuken-1 receptor antagonist
US6416753B1 (en) * 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
EP2002846B1 (en) * 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6063600A (en) * 1997-05-23 2000-05-16 Uab Research Foundation DNA encoding canine interleukin-1 receptor antagonist
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6287516B1 (en) 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US7029861B1 (en) 1998-09-15 2006-04-18 Board Of Regents, The University Of Texas System LPS-response gene compositions and methods
DE19903876B4 (en) * 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Process for the in vitro formation and accumulation of interleukin-1 receptor antagonists
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
PT1183362E (en) * 1999-05-25 2007-04-30 Immunex Corp Il-1 eta dna and polypeptides
US6736972B1 (en) * 2000-03-24 2004-05-18 Immunocept, L.L.C. Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
AU2003255276A1 (en) * 2002-08-13 2004-02-25 Arbios Systems, Inc. Selective plasma exchange therapy
EA007473B1 (en) * 2004-06-07 2006-10-27 Алексей Михайлович Федорук Method for treating pancreatitis
EP2609141A1 (en) 2010-08-23 2013-07-03 Dow Corning Corporation Emulsions containing saccharide siloxane copolymer emulsifiers and methods for their preparation and use
CN103154092A (en) 2010-08-23 2013-06-12 道康宁公司 Emulsions containing saccharide siloxane copolymer emulsifiers and methods for their preparation and use
WO2012027143A1 (en) 2010-08-23 2012-03-01 Dow Corning Corporation Saccharide siloxane copolymers and methods for their preparation and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522827A (en) * 1982-07-02 1985-06-11 Knoll Ag Method of treating acute pancreatitis with isometheptene
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3681408D1 (en) * 1985-11-12 1991-10-17 Ono Pharmaceutical Co. Ltd., Osaka, Jp
US4902708A (en) * 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
GB8900812D0 (en) * 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
AU9106491A (en) * 1991-01-17 1992-08-27 Upjohn Company, The Method of preventing and treating insulin dependent diabetes mellitus
US5220018A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5225182A (en) * 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5508262A (en) * 1993-12-15 1996-04-16 University Of South Florida Interleukin-1 receptor antagonist decreases severity of acute pancreatitis

Also Published As

Publication number Publication date
US5508262A (en) 1996-04-16
EP0734395A1 (en) 1996-10-02
EP0734395A4 (en) 1997-03-19
JPH09510434A (en) 1997-10-21
US5919444A (en) 1999-07-06
WO1995016706A1 (en) 1995-06-22
CA2179183C (en) 2006-12-05

Similar Documents

Publication Publication Date Title
CA2179183A1 (en) Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
HUP9900028A3 (en) Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
CA2004598A1 (en) Medicinal aerosol formulations
CA2213339A1 (en) Method of treating adenosine depletion
CA2116238A1 (en) Oral 1 .alpha.-hydroxyprevitamin d
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
CA2259148A1 (en) Solid oral dosage forms of valsartan
HUP9901215A3 (en) Microemulsions for use as vehicles for administration of active compounds
EP0648492A3 (en) Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof.
CA2226582A1 (en) Non-allosteric gabaa agonists for treating sleep disorders
CA2128142A1 (en) Pharmaceutical combination containing ras inhibitor and endothelin antagonist for the treatment of cardiovascular disorders
AU6691194A (en) N'-heterocyclyl-n-benzofuranyl urea derivatives and their analogs as acat inhibitors
HUP9901437A3 (en) Pharmaceutical formulation, containing amoxycillin and clavulanate
PL312354A1 (en) 2,9-disubstituted purin-6-ones method of obtaining and therapeutic agents containing them
AU1429697A (en) Systems and methods for the transdermal administration of androgenic agents
AU4480993A (en) Polydimethylsiloxanes for modulus reduction and method for their preparation
CA2118512A1 (en) Agents for treating substance abuse disorders
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
HUP9901990A2 (en) Furan- and thiophene derivatives having inhibitor effect on the replication of hiv-1 and hiv-1 mutants, and medicaments containing the same
AU623165B2 (en) Method of inhibiting the spread of disease and infection in structures
CA2218643A1 (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
HK1015273A1 (en) Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral.
AU1251295A (en) Substituted benzimidazole, processes for its preparation and its pharmaceutical use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed